Importantly, these EMT-associated signaling pathways also have roles in conferring resistance to inhibitors of BRAF/MEK, hindering therapeutic outcomes in patients with metastatic melanoma driven by BRAF mutations. The gene discussed is BRAF; the disease is metastatic melanoma.